Michelle DeWindt brings over a decade of experience in diabetes care to her role as Clinical Specialist at Ascensia Diabetes Care. With a background as a Physician Assistant and former Patient Care Educator, Michelle now leads customer education and onboarding for the Eversense^® Continuous Glucose Monitoring (CGM) system—the world’s only CGM that lasts for up to one year. Her work helps ensure patients and healthcare providers fully understand the system’s distinct advantages, including its exceptional accuracy with almost no false compression lows^*1, the ability to remove and reapply the transmitter^*2 without wasting a sensor, and its gentleness on the skin.

At Ascensia, Michelle designs and delivers personalized training that explains how Eversense^® works, what to expect from the insertion procedure, how to manage the system day-to-day, and how to interpret glucose data. She also collaborates with internal teams on training logistics, digital tools, and patient materials, always focused on making the onboarding process seamless and impactful.

I joined the predecessor of Wemex, the former Medicom Solution Co., Ltd., as a new graduate in 2011. Since then, I have worked as a coordinator at the Shonan Sales Office in Japan. This role involves a variety of responsibilities, including delivering products, providing operational instructions, offering after-sales service, and proposing new solutions to customers who have installed Wemex’s electronic medical records and medical-receipt computers. This role places me in direct contact with our customers, making me feel like the closest link between them and Wemex. At the same time, I recognize that another crucial aspect of my work is to relay valuable feedback from customers to the company, contributing to improved services and quality.

The Shonan Sales Office, where I work, central and western areas of Kanagawa Prefecture, Japan, and Machida City, Tokyo. We have a total of 15 members, including 10 coordinators, 4 sales representatives, and 1 administrative staff. Together, we support approximately 600 customers. Despite managing such a large number of customers, we continuously pursue various initiatives to provide high-quality services and maintain excellent standards.

My name is Philip Kyd, and I have been a part of the driving force for precision and innovation at Epredia for over eight years.

As the Director of Strategic Operations and Transformation and Deputy Site Director, I lead a global, multidisciplinary team dedicated to designing, developing, and scaling advanced consumables that enhance the pathology workflow. Our team’s expertise spans mechanical engineering, chemistry, project management, verification and validation, enabling the delivery of solutions that align with clinical needs and elevate patient care.

One of our most exciting innovations is the SuperFrost PLUS adhesion slide-engineered with advanced adhesion properties to ensure tissue sections remain securely in place during even the most rigorous staining protocols, including H&E, special stains, and immunohistochemistry. This product exemplifies Epredia’s relentless commitment to precision technology and positively consistent performance. The reliable adhesion slide enables healthcare professionals to streamline workflow and make confident diagnoses in clinical practices, while empowering researchers to pursue more complex experimentation and discovery, including applications in digital pathology, whole-slide imaging, and AI-powered image analysis. By elevating adhesion technology, we have not only enhanced the reliability of tissue handling but also encouraged clinicians and researchers to achieve more precise and meaningful results. Ultimately, we believe that our innovation through such precision technologies will not only support personalized medicine but also lead to the pursuit of new possibilities in healthcare and research.

I have been engaged in the development of blood glucose sensors in the In Vitro Diagnostics Division for many years. Currently, I am leveraging this expertise to lead the development of cell culture sensors in the Biosensor Development Department.

The Biosensor Development Department is committed to creating new value in the field of cell and gene therapy (CGT) by building on the advanced technology cultivated over more than 30 years of blood glucose sensor development. Blood glucose monitoring technology, which requires exceptional precision and reliability, is one of the core technologies that underpin PHC Group. Applying this technology, we have developed a high-precision “In-Line Monitoring Technology” that enables real-time, continuous measurement of metabolic data such as glucose consumption and lactate production during cell culture. This technology was incorporated into the Live Cell Metabolic Analyzer (LiCellMo™) launched by the Biomedical Division in September of last year.